文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

兔内毒素休克模型中血管反应性的器官特异性变化及诱导型一氧化氮合酶与内皮素-1的作用

Organ-specific changes in vascular reactivity and roles of inducible nitric oxide synthase and endothelin-1 in a rabbit endotoxic shock model.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论内毒素休克兔模型显示血管反应性变化呈器官特异性,晚期iNOS和ET-1表达升高且与血管反应性下降负相关,氨基胍和PD-142893可改善血管反应性与器官灌注。

该研究在兔内毒素休克模型中,给予脂多糖(1 mg/kg)诱导内毒素休克,观察肠系膜上动脉、腹腔动脉和左肾动脉的血管反应性变化,并检测iNOS和ET-1的表达。结果显示,三条动脉的血管反应性在早期升高、晚期降低;肠系膜上动脉对去甲肾上腺素(NE,34.9%)和乙酰胆碱(Ach,32.3%)的反应性下降幅度最大,其次为左肾动脉(NE,33.7%;Ach,30.5%)和腹腔动脉(NE,16.2%),而腹腔动脉对Ach的舒张反应性增加至159%。iNOS和ET-1的mRNA及蛋白水平在早期未受影响,晚期显著升高,且在肠系膜上动脉中表达最高,与血管反应性下降呈负相关。iNOS抑制剂氨基胍(20 mg/kg)和ET-1抑制剂PD-142893(0.02 mg/kg)可显著改善血管反应性和器官灌注,并稳定血流动力学参数。

要点

  • 内毒素休克兔模型中,肠系膜上动脉、腹腔动脉和左肾动脉的血管反应性在早期升高、晚期降低。
  • 肠系膜上动脉对去甲肾上腺素(34.9%)和乙酰胆碱(32.3%)的反应性下降幅度最大,腹腔动脉对去甲肾上腺素的下降幅度为16.2%,左肾动脉对去甲肾上腺素和乙酰胆碱的下降幅度分别为33.7%和30.5%。
  • 腹腔动脉对乙酰胆碱的舒张反应性增加至159%。
  • iNOS和ET-1的mRNA及蛋白水平在晚期显著升高,肠系膜上动脉表达高于腹腔动脉和左肾动脉,且与血管反应性下降呈负相关。
  • 氨基胍(20 mg/kg)和PD-142893(0.02 mg/kg)可显著改善内毒素休克兔的血管反应性和器官灌注,并稳定血流动力学参数。

适用人群与场景

  • 内毒素休克兔模型(脂多糖1 mg/kg诱导),观察肠系膜上动脉、腹腔动脉和左肾动脉的血管反应性。

处置流程与药物剂量

  • 氨基胍(iNOS抑制剂)20 mg/kg,用于内毒素休克兔,可显著改善血管反应性和器官灌注,并稳定血流动力学参数。
  • PD-142893(ET-1抑制剂)0.02 mg/kg,用于内毒素休克兔,可显著改善血管反应性和器官灌注,并稳定血流动力学参数。

研究设计与关键结果

  • 研究类型:兔内毒素休克模型实验;样本量原文未报告;人群:兔;干预:脂多糖(1 mg/kg)诱导内毒素休克,观察肠系膜上动脉、腹腔动脉和左肾动脉的血管反应性,并检测iNOS和ET-1表达。
  • 主要结果:肠系膜上动脉、腹腔动脉和左肾动脉的血管反应性在早期升高、晚期降低;肠系膜上动脉对去甲肾上腺素和乙酰胆碱的反应性下降幅度最大(分别为34.9%和32.3%),其次为左肾动脉(去甲肾上腺素33.7%,乙酰胆碱30.5%),腹腔动脉对去甲肾上腺素的下降幅度为16.2%,而腹腔动脉对乙酰胆碱的舒张反应性增加至159%。
  • 机制结果:iNOS和ET-1的mRNA及蛋白水平在早期未受影响,晚期显著升高;肠系膜上动脉表达高于腹腔动脉和左肾动脉,且与血管反应性下降呈负相关。
  • 干预结果:氨基胍(20 mg/kg)和PD-142893(0.02 mg/kg)可显著改善血管反应性和器官灌注,并稳定血流动力学参数。

证据类型、等级与局限

  • 证据类型:动物实验(治疗性研究,证据等级II级)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该动物实验提示内毒素休克时血管反应性变化呈器官特异性,iNOS和ET-1在不同血管的差异表达可能参与该器官特异性;氨基胍和PD-142893在兔内毒素休克模型中可改善血管反应性和器官灌注,并稳定血流动力学参数,但尚未在人体验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhagic shock-induced changes in vascular reactivity appear organ-specific. In the present study, we examined the hypothesis that vascular reactivity induced by septic shock similarly displays organ-specific differences and is regulated by inducible nitric oxide synthase (iNOS) and endothelin-1 (ET-1).

METHODS: Endotoxic shock was induced in rabbits by administration of lipopolysaccharide (LPS) (1 mg/kg), and organ specificity of vascular reactivity of superior mesenteric artery (SMA), celiac artery (CA), and left renal artery (LRA) as well as the potential involvement of iNOS and ET-1 examined.

RESULTS: Vascular reactivity of SMA, CA, and LRA was increased at the early stages and decreased at the late stages after LPS administration. Superior mesenteric artery showed the greatest decrease in vascular reactivity in response to norepinephrine (NE) (34.9%) and acetylcholine (Ach; 32.3%), followed by LRA (NE, 33.7%; Ach, 30.5%) and CA (NE, 16.2%), whereas the relaxation reactivity of CA in response to Ach was increased to 159%. The mRNA and protein levels of iNOS and ET-1 in SMA, CA, and LRA were not affected at the early stages of endotoxic shock after LPS administration but significantly increased at the late stages. Expression levels were higher in SMA than CA and LRA and negatively correlated with the decrease in vascular reactivity. The iNOS and ET-1 inhibitors, aminoguanidine (20 mg/kg) and PD-142893 (0.02 mg/kg), respectively, induced significant improvements in vascular reactivity and organ perfusion and stabilized the hemodynamic parameters in rabbits subjected to endotoxic shock.

CONCLUSION: Changes in vascular reactivity during endotoxic shock are organ-specific. Differential expression patterns of iNOS and ET-1 in different blood vessels contribute to the organ specificity of vascular reactivity.

LEVEL OF EVIDENCE: Therapeutic study, level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Zhang ZS, Chen W, Li T, et al. Organ-specific changes in vascular reactivity and roles of inducible nitric oxide synthase and endothelin-1 in a rabbit endotoxic shock model. J Trauma Acute Care Surg. 2018. PMID: 30086070. doi:10.1097/TA.0000000000002036

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。